Brokerages expect Bioverativ Inc (NASDAQ:BIVV) to report sales of $333.33 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Bioverativ’s earnings, with estimates ranging from $328.00 million to $339.30 million. Bioverativ posted sales of $259.10 million during the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The business is expected to issue its next earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that Bioverativ will report full year sales of $333.33 million for the current year, with estimates ranging from $1.38 billion to $1.43 billion. For the next financial year, analysts expect that the company will post sales of $1.44 billion per share, with estimates ranging from $1.30 billion to $1.53 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Bioverativ.
Several analysts recently commented on the stock. Credit Suisse Group reiterated a “neutral” rating on shares of Bioverativ in a research note on Wednesday, January 24th. Jefferies Group cut shares of Bioverativ from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. Argus reiterated a “hold” rating on shares of Bioverativ in a research note on Wednesday, January 24th. Morgan Stanley upgraded shares of Bioverativ from an “underweight” rating to an “equal weight” rating in a research note on Tuesday, January 23rd. Finally, Zacks Investment Research cut shares of Bioverativ from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Thirteen investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Bioverativ has an average rating of “Hold” and a consensus target price of $63.15.
Shares of Bioverativ (NASDAQ BIVV) opened at $103.61 on Friday. Bioverativ has a 52 week low of $43.52 and a 52 week high of $104.30. The company has a market cap of $11,213.09 and a price-to-earnings ratio of 31.59.
Institutional investors and hedge funds have recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. acquired a new position in Bioverativ during the fourth quarter worth about $105,000. American Assets Investment Management LLC acquired a new position in Bioverativ during the fourth quarter worth about $108,000. Advisors Asset Management Inc. acquired a new position in Bioverativ during the third quarter worth about $137,000. TCI Wealth Advisors Inc. acquired a new position in Bioverativ during the third quarter worth about $186,000. Finally, Ladenburg Thalmann Financial Services Inc. acquired a new position in Bioverativ during the third quarter worth about $190,000. Institutional investors own 94.10% of the company’s stock.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.